Identification of microRNAs involved in gefitinib resistance of non-small-cell lung cancer through the insulin-like growth factor receptor 1 signaling pathway

Multiple clinical and experimental studies have suggested that epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) may be effective at treating advanced non-small cell lung cancer (NSCLC), however, the molecular basis of primary resistance to EGFR-TKIs in NSCLC remains unclear. I...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Experimental and therapeutic medicine 2017-10, Vol.14 (4), p.2853-2862
Hauptverfasser: Ma, Wei, Kang, Yanhong, Ning, Lanlan, Tan, Jie, Wang, Hanping, Ying, Yi
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 2862
container_issue 4
container_start_page 2853
container_title Experimental and therapeutic medicine
container_volume 14
creator Ma, Wei
Kang, Yanhong
Ning, Lanlan
Tan, Jie
Wang, Hanping
Ying, Yi
description Multiple clinical and experimental studies have suggested that epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) may be effective at treating advanced non-small cell lung cancer (NSCLC), however, the molecular basis of primary resistance to EGFR-TKIs in NSCLC remains unclear. In the current study, the insulin-like growth factor 1 receptor (IGF-1R) gene in the gefitinib-resistant human lung adenocarcinoma epithelial cell line A549 (A549/GR) was silenced using small interfering RNA (siRNA) in order to determine the role of microRNA (miRNA) in the development of resistance against epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) in lung adenocarcinoma. The relative gefitinib-resistant capacity in A549 and A549/GR cells was determined using a cell counting kit 8. A549/GR cells were transfected with chemically synthesized siRNA to silence the IGF-1R gene. A total of 48 h after siRNA transfection, IGF-1R expression in A549/GR cells was evaluated using reverse transcription-quantitative polymerase chain reaction (RT-qPCR) and western blotting. miRNA expression in A549/GR cells and A549/GR cells with silenced IGF-1R was analyzed using a miRNA microarray. The microarray results of 10 miRNAs were then compared with the results of RT-qPCR. The results demonstrated that the gefitinib-resistance capacity of A549/GR cells was six times higher than that of A549 cells. Additionally, RT-qPCR and western blotting demonstrated that the IGF-1R gene in A549/GR cells was successfully silenced by siRNA. The highest silencing rate (72%) of the IGF-1R gene was obtained using siRNA-2. The microarray identified 72 miRNAs with significantly different expression in A549/GR cells with silenced IGF-1R compared with A549/GR cells. Of the 72 differentially expressed miRNAs, 13 miRNAs (including miR-497-3p and miR-1273c) were up-regulated and 59 miRNAs (including miR-361-3p and miR-345-3p) were down-regulated in A549/GR cells with silenced IGF-1R compared with A549/GR cells. The changes in the expression of 10 different miRNAs were confirmed by RT-qPCR. Thus, the present study successfully established an A549/GR cell line with silenced IGF-1R. The results suggest that a number of miRNAs associated with the IGF-1R signaling pathway, including miR-497-3p and miR-144-5p, were involved in the development of resistance against EGFR-TKIs in A549 cells. These miRNAs may provide novel targets to treat lung adenocarcinoma exhibiting resistance against EG
doi_str_mv 10.3892/etm.2017.4847
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5585727</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1979111433</sourcerecordid><originalsourceid>FETCH-LOGICAL-c415t-dfd3832d21b42375f766828e16b60291b42ddd68e2a947890ff6eadda9b61bcc3</originalsourceid><addsrcrecordid>eNpdkU1rFTEUhoMottQu3UrAjZu5JpmPJBuhFG0LRUF0HTL5mEnNJNckc0v_jL_VDL0WNZtzyHnykvO-ALzGaNcyTt6bsuwIwnTXsY4-A6eYctJghPvnxx5xhk_Aec53qJ5-wIz1L8EJYRyT-uQU_LrRJhRnnZLFxQCjhYtTKX79fJGhC4foD0bXBk7GuuKCG2Ey2eUigzIbHWJo8iK9b5TxHvo1TFBtwwTLnOI6zbWaqpBX70Lj3Q8DpxTvywytVCWmqqfMfmswzG4KsmIT3Msy38uHV-CFlT6b82M9A98_ffx2ed3cfrm6uby4bVSH-9Joq1vWEk3w2JGW9pYOAyPM4GEcEOHbrdZ6YIZI3lHGkbWDkVpLPg54VKo9Ax8edffruBitqidJerFPbpHpQUTpxL-T4GYxxYPoe9ZTQqvAu6NAij9Xk4tYXN4ckcHENQvMu-o_Yi2q6Nv_0Lu4prr3RlGOMe7atlLNI1XDyDkZ-_QZjMQWvqjhiy18sYVf-Td_b_BE_4m6_Q3dFa7k</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1979111433</pqid></control><display><type>article</type><title>Identification of microRNAs involved in gefitinib resistance of non-small-cell lung cancer through the insulin-like growth factor receptor 1 signaling pathway</title><source>PubMed Central</source><creator>Ma, Wei ; Kang, Yanhong ; Ning, Lanlan ; Tan, Jie ; Wang, Hanping ; Ying, Yi</creator><creatorcontrib>Ma, Wei ; Kang, Yanhong ; Ning, Lanlan ; Tan, Jie ; Wang, Hanping ; Ying, Yi</creatorcontrib><description>Multiple clinical and experimental studies have suggested that epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) may be effective at treating advanced non-small cell lung cancer (NSCLC), however, the molecular basis of primary resistance to EGFR-TKIs in NSCLC remains unclear. In the current study, the insulin-like growth factor 1 receptor (IGF-1R) gene in the gefitinib-resistant human lung adenocarcinoma epithelial cell line A549 (A549/GR) was silenced using small interfering RNA (siRNA) in order to determine the role of microRNA (miRNA) in the development of resistance against epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) in lung adenocarcinoma. The relative gefitinib-resistant capacity in A549 and A549/GR cells was determined using a cell counting kit 8. A549/GR cells were transfected with chemically synthesized siRNA to silence the IGF-1R gene. A total of 48 h after siRNA transfection, IGF-1R expression in A549/GR cells was evaluated using reverse transcription-quantitative polymerase chain reaction (RT-qPCR) and western blotting. miRNA expression in A549/GR cells and A549/GR cells with silenced IGF-1R was analyzed using a miRNA microarray. The microarray results of 10 miRNAs were then compared with the results of RT-qPCR. The results demonstrated that the gefitinib-resistance capacity of A549/GR cells was six times higher than that of A549 cells. Additionally, RT-qPCR and western blotting demonstrated that the IGF-1R gene in A549/GR cells was successfully silenced by siRNA. The highest silencing rate (72%) of the IGF-1R gene was obtained using siRNA-2. The microarray identified 72 miRNAs with significantly different expression in A549/GR cells with silenced IGF-1R compared with A549/GR cells. Of the 72 differentially expressed miRNAs, 13 miRNAs (including miR-497-3p and miR-1273c) were up-regulated and 59 miRNAs (including miR-361-3p and miR-345-3p) were down-regulated in A549/GR cells with silenced IGF-1R compared with A549/GR cells. The changes in the expression of 10 different miRNAs were confirmed by RT-qPCR. Thus, the present study successfully established an A549/GR cell line with silenced IGF-1R. The results suggest that a number of miRNAs associated with the IGF-1R signaling pathway, including miR-497-3p and miR-144-5p, were involved in the development of resistance against EGFR-TKIs in A549 cells. These miRNAs may provide novel targets to treat lung adenocarcinoma exhibiting resistance against EGFR-TKIs.</description><identifier>ISSN: 1792-0981</identifier><identifier>EISSN: 1792-1015</identifier><identifier>DOI: 10.3892/etm.2017.4847</identifier><identifier>PMID: 28912847</identifier><language>eng</language><publisher>Greece: Spandidos Publications UK Ltd</publisher><subject>Drug resistance ; Epidermal growth factor ; Inhibitor drugs ; Insulin-like growth factors ; Kinases ; Lung cancer ; Metastasis ; MicroRNAs ; Mutation ; Proteins ; Studies ; Targeted cancer therapy ; Tumors</subject><ispartof>Experimental and therapeutic medicine, 2017-10, Vol.14 (4), p.2853-2862</ispartof><rights>Copyright Spandidos Publications UK Ltd. 2017</rights><rights>Copyright: © Ma et al. 2017</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c415t-dfd3832d21b42375f766828e16b60291b42ddd68e2a947890ff6eadda9b61bcc3</citedby><cites>FETCH-LOGICAL-c415t-dfd3832d21b42375f766828e16b60291b42ddd68e2a947890ff6eadda9b61bcc3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5585727/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5585727/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28912847$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ma, Wei</creatorcontrib><creatorcontrib>Kang, Yanhong</creatorcontrib><creatorcontrib>Ning, Lanlan</creatorcontrib><creatorcontrib>Tan, Jie</creatorcontrib><creatorcontrib>Wang, Hanping</creatorcontrib><creatorcontrib>Ying, Yi</creatorcontrib><title>Identification of microRNAs involved in gefitinib resistance of non-small-cell lung cancer through the insulin-like growth factor receptor 1 signaling pathway</title><title>Experimental and therapeutic medicine</title><addtitle>Exp Ther Med</addtitle><description>Multiple clinical and experimental studies have suggested that epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) may be effective at treating advanced non-small cell lung cancer (NSCLC), however, the molecular basis of primary resistance to EGFR-TKIs in NSCLC remains unclear. In the current study, the insulin-like growth factor 1 receptor (IGF-1R) gene in the gefitinib-resistant human lung adenocarcinoma epithelial cell line A549 (A549/GR) was silenced using small interfering RNA (siRNA) in order to determine the role of microRNA (miRNA) in the development of resistance against epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) in lung adenocarcinoma. The relative gefitinib-resistant capacity in A549 and A549/GR cells was determined using a cell counting kit 8. A549/GR cells were transfected with chemically synthesized siRNA to silence the IGF-1R gene. A total of 48 h after siRNA transfection, IGF-1R expression in A549/GR cells was evaluated using reverse transcription-quantitative polymerase chain reaction (RT-qPCR) and western blotting. miRNA expression in A549/GR cells and A549/GR cells with silenced IGF-1R was analyzed using a miRNA microarray. The microarray results of 10 miRNAs were then compared with the results of RT-qPCR. The results demonstrated that the gefitinib-resistance capacity of A549/GR cells was six times higher than that of A549 cells. Additionally, RT-qPCR and western blotting demonstrated that the IGF-1R gene in A549/GR cells was successfully silenced by siRNA. The highest silencing rate (72%) of the IGF-1R gene was obtained using siRNA-2. The microarray identified 72 miRNAs with significantly different expression in A549/GR cells with silenced IGF-1R compared with A549/GR cells. Of the 72 differentially expressed miRNAs, 13 miRNAs (including miR-497-3p and miR-1273c) were up-regulated and 59 miRNAs (including miR-361-3p and miR-345-3p) were down-regulated in A549/GR cells with silenced IGF-1R compared with A549/GR cells. The changes in the expression of 10 different miRNAs were confirmed by RT-qPCR. Thus, the present study successfully established an A549/GR cell line with silenced IGF-1R. The results suggest that a number of miRNAs associated with the IGF-1R signaling pathway, including miR-497-3p and miR-144-5p, were involved in the development of resistance against EGFR-TKIs in A549 cells. These miRNAs may provide novel targets to treat lung adenocarcinoma exhibiting resistance against EGFR-TKIs.</description><subject>Drug resistance</subject><subject>Epidermal growth factor</subject><subject>Inhibitor drugs</subject><subject>Insulin-like growth factors</subject><subject>Kinases</subject><subject>Lung cancer</subject><subject>Metastasis</subject><subject>MicroRNAs</subject><subject>Mutation</subject><subject>Proteins</subject><subject>Studies</subject><subject>Targeted cancer therapy</subject><subject>Tumors</subject><issn>1792-0981</issn><issn>1792-1015</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>BENPR</sourceid><recordid>eNpdkU1rFTEUhoMottQu3UrAjZu5JpmPJBuhFG0LRUF0HTL5mEnNJNckc0v_jL_VDL0WNZtzyHnykvO-ALzGaNcyTt6bsuwIwnTXsY4-A6eYctJghPvnxx5xhk_Aec53qJ5-wIz1L8EJYRyT-uQU_LrRJhRnnZLFxQCjhYtTKX79fJGhC4foD0bXBk7GuuKCG2Ey2eUigzIbHWJo8iK9b5TxHvo1TFBtwwTLnOI6zbWaqpBX70Lj3Q8DpxTvywytVCWmqqfMfmswzG4KsmIT3Msy38uHV-CFlT6b82M9A98_ffx2ed3cfrm6uby4bVSH-9Joq1vWEk3w2JGW9pYOAyPM4GEcEOHbrdZ6YIZI3lHGkbWDkVpLPg54VKo9Ax8edffruBitqidJerFPbpHpQUTpxL-T4GYxxYPoe9ZTQqvAu6NAij9Xk4tYXN4ckcHENQvMu-o_Yi2q6Nv_0Lu4prr3RlGOMe7atlLNI1XDyDkZ-_QZjMQWvqjhiy18sYVf-Td_b_BE_4m6_Q3dFa7k</recordid><startdate>20171001</startdate><enddate>20171001</enddate><creator>Ma, Wei</creator><creator>Kang, Yanhong</creator><creator>Ning, Lanlan</creator><creator>Tan, Jie</creator><creator>Wang, Hanping</creator><creator>Ying, Yi</creator><general>Spandidos Publications UK Ltd</general><general>D.A. Spandidos</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20171001</creationdate><title>Identification of microRNAs involved in gefitinib resistance of non-small-cell lung cancer through the insulin-like growth factor receptor 1 signaling pathway</title><author>Ma, Wei ; Kang, Yanhong ; Ning, Lanlan ; Tan, Jie ; Wang, Hanping ; Ying, Yi</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c415t-dfd3832d21b42375f766828e16b60291b42ddd68e2a947890ff6eadda9b61bcc3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Drug resistance</topic><topic>Epidermal growth factor</topic><topic>Inhibitor drugs</topic><topic>Insulin-like growth factors</topic><topic>Kinases</topic><topic>Lung cancer</topic><topic>Metastasis</topic><topic>MicroRNAs</topic><topic>Mutation</topic><topic>Proteins</topic><topic>Studies</topic><topic>Targeted cancer therapy</topic><topic>Tumors</topic><toplevel>online_resources</toplevel><creatorcontrib>Ma, Wei</creatorcontrib><creatorcontrib>Kang, Yanhong</creatorcontrib><creatorcontrib>Ning, Lanlan</creatorcontrib><creatorcontrib>Tan, Jie</creatorcontrib><creatorcontrib>Wang, Hanping</creatorcontrib><creatorcontrib>Ying, Yi</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing &amp; Allied Health Database</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Database (Alumni Edition)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Experimental and therapeutic medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ma, Wei</au><au>Kang, Yanhong</au><au>Ning, Lanlan</au><au>Tan, Jie</au><au>Wang, Hanping</au><au>Ying, Yi</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Identification of microRNAs involved in gefitinib resistance of non-small-cell lung cancer through the insulin-like growth factor receptor 1 signaling pathway</atitle><jtitle>Experimental and therapeutic medicine</jtitle><addtitle>Exp Ther Med</addtitle><date>2017-10-01</date><risdate>2017</risdate><volume>14</volume><issue>4</issue><spage>2853</spage><epage>2862</epage><pages>2853-2862</pages><issn>1792-0981</issn><eissn>1792-1015</eissn><abstract>Multiple clinical and experimental studies have suggested that epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) may be effective at treating advanced non-small cell lung cancer (NSCLC), however, the molecular basis of primary resistance to EGFR-TKIs in NSCLC remains unclear. In the current study, the insulin-like growth factor 1 receptor (IGF-1R) gene in the gefitinib-resistant human lung adenocarcinoma epithelial cell line A549 (A549/GR) was silenced using small interfering RNA (siRNA) in order to determine the role of microRNA (miRNA) in the development of resistance against epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) in lung adenocarcinoma. The relative gefitinib-resistant capacity in A549 and A549/GR cells was determined using a cell counting kit 8. A549/GR cells were transfected with chemically synthesized siRNA to silence the IGF-1R gene. A total of 48 h after siRNA transfection, IGF-1R expression in A549/GR cells was evaluated using reverse transcription-quantitative polymerase chain reaction (RT-qPCR) and western blotting. miRNA expression in A549/GR cells and A549/GR cells with silenced IGF-1R was analyzed using a miRNA microarray. The microarray results of 10 miRNAs were then compared with the results of RT-qPCR. The results demonstrated that the gefitinib-resistance capacity of A549/GR cells was six times higher than that of A549 cells. Additionally, RT-qPCR and western blotting demonstrated that the IGF-1R gene in A549/GR cells was successfully silenced by siRNA. The highest silencing rate (72%) of the IGF-1R gene was obtained using siRNA-2. The microarray identified 72 miRNAs with significantly different expression in A549/GR cells with silenced IGF-1R compared with A549/GR cells. Of the 72 differentially expressed miRNAs, 13 miRNAs (including miR-497-3p and miR-1273c) were up-regulated and 59 miRNAs (including miR-361-3p and miR-345-3p) were down-regulated in A549/GR cells with silenced IGF-1R compared with A549/GR cells. The changes in the expression of 10 different miRNAs were confirmed by RT-qPCR. Thus, the present study successfully established an A549/GR cell line with silenced IGF-1R. The results suggest that a number of miRNAs associated with the IGF-1R signaling pathway, including miR-497-3p and miR-144-5p, were involved in the development of resistance against EGFR-TKIs in A549 cells. These miRNAs may provide novel targets to treat lung adenocarcinoma exhibiting resistance against EGFR-TKIs.</abstract><cop>Greece</cop><pub>Spandidos Publications UK Ltd</pub><pmid>28912847</pmid><doi>10.3892/etm.2017.4847</doi><tpages>10</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1792-0981
ispartof Experimental and therapeutic medicine, 2017-10, Vol.14 (4), p.2853-2862
issn 1792-0981
1792-1015
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5585727
source PubMed Central
subjects Drug resistance
Epidermal growth factor
Inhibitor drugs
Insulin-like growth factors
Kinases
Lung cancer
Metastasis
MicroRNAs
Mutation
Proteins
Studies
Targeted cancer therapy
Tumors
title Identification of microRNAs involved in gefitinib resistance of non-small-cell lung cancer through the insulin-like growth factor receptor 1 signaling pathway
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-08T12%3A29%3A36IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Identification%20of%20microRNAs%20involved%20in%20gefitinib%20resistance%20of%20non-small-cell%20lung%20cancer%20through%20the%20insulin-like%20growth%20factor%20receptor%201%20signaling%20pathway&rft.jtitle=Experimental%20and%20therapeutic%20medicine&rft.au=Ma,%20Wei&rft.date=2017-10-01&rft.volume=14&rft.issue=4&rft.spage=2853&rft.epage=2862&rft.pages=2853-2862&rft.issn=1792-0981&rft.eissn=1792-1015&rft_id=info:doi/10.3892/etm.2017.4847&rft_dat=%3Cproquest_pubme%3E1979111433%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1979111433&rft_id=info:pmid/28912847&rfr_iscdi=true